Treatment of rosacea

Details Treatment of rosacea Treatment of rosacea

Filed on

2006-12-26

Date issued

2006-12-26

Examiner

Russel, Jeffrey Edwin (Department: 1654)

Patent Class

Drug, bio-affecting and body treating compositions

SubClass

Designated organic active ingredient containing

SubSubClass

Peptide containing doai

Other Related Categories

C514S009100, C514S024000, C514S398000

Type

Reexamination Certificate

Status

active

Patent number

07153826

Description

ABSTRACT:
Cyclic peptide antibiotics including the loloatins are effective in the treatment of rosacea, particularly when administered in conjunction with an antibiotic such as metronidazole that is effective against anaerobic bacteria.

REFERENCES:
patent: 4510132 (1985-04-01), Vaara
patent: 5776919 (1998-07-01), Sukigara et al.
patent: 5998200 (1999-12-01), Bonaventura et al.
patent: 6509014 (2003-01-01), De Lacharriere et al.
patent: 6794490 (2004-09-01), Hill et al.
patent: 6911525 (2005-06-01), Hill et al.
patent: 2005/0009747 (2005-01-01), Kelleher et al.
patent: WO 95/05852 (1995-03-01), None
patent: WO 98/04584 (1998-02-01), None
Derwent-Acc-No. 1991-175665. Abstract of RO 99845 A (Sep. 28, 1990).
BPI: “Rote Liste 1992” Editio Cantor, Autendorf, Germany.
Singer (1998) “Drug therapy of Rosacea: A problem-directed approach” J. Cutan. Med. Surg. 2(Supp 4):S4-20-S4-23.
Gerard, et al., “Loloatin B, A Cyclic Decapeptide Antibiotic Produced in Culture by a Tropical Marine Bacterium” Tetrahedron Letters 37: 7201-7204. (1996).

Affiliated with

Also associated with

Rating

Treatment of rosacea does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of rosacea, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of rosacea will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3715963